Does the media refer more to SLDB or LFCR?

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Lifecore Biomedical's average media sentiment score of 1.89 beat Solid Biosciences' score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ESPR or LFCR?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Esperion Therapeutics' score of 1.42 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer LFCR or EVMN?

In the previous week, Evommune had 11 more articles in the media than Lifecore Biomedical. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Evommune's score of -0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evommune 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable earnings & valuation, LFCR or VOR?

Vor Biopharma has lower revenue, but higher earnings than Lifecore Biomedical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifecore Biomedical $128.87M 1.53 -$35.26M -$0.94 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media prefer LFCR or VOR?

In the previous week, Vor Biopharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lifecore Biomedical (LFCR) Competitors

$5.25 +0.29 (+5.85%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$5.25 0.00 (0.00%)

As of 06/30/2026 04:51 PM Eastern

Compare

LFCR vs. ANNX, SLDB, ESPR, EVMN, and VOR

Should you buy Lifecore Biomedical stock or one of its competitors? MarketBeat compares Lifecore Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifecore Biomedical include Annexon (ANNX), Solid Biosciences (SLDB), Esperion Therapeutics (ESPR), Evommune (EVMN), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

How does Lifecore Biomedical compare to Annexon?

Annexon (NASDAQ:ANNX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

In the previous week, Lifecore Biomedical had 1 more articles in the media than Annexon. MarketBeat recorded 2 mentions for Lifecore Biomedical and 1 mentions for Annexon. Lifecore Biomedical's average media sentiment score of 1.89 beat Annexon's score of 1.87 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Annexon	Very Positive
Lifecore Biomedical	Very Positive

83.4% of Lifecore Biomedical shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Annexon has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Annexon's return on equity of -101.19% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Lifecore Biomedical has higher revenue and earnings than Annexon. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A

Annexon currently has a consensus price target of $16.00, suggesting a potential upside of 180.21%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 23.81%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifecore Biomedical beats Annexon on 8 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Solid Biosciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Solid Biosciences' return on equity of -73.42% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Lifecore Biomedical's average media sentiment score of 1.89 beat Solid Biosciences' score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lifecore Biomedical has higher revenue and earnings than Solid Biosciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A

Solid Biosciences currently has a consensus price target of $17.00, suggesting a potential upside of 70.17%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 23.81%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Solid Biosciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Solid Biosciences beats Lifecore Biomedical on 8 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Esperion Therapeutics has a net margin of 0.12% compared to Lifecore Biomedical's net margin of -25.43%. Esperion Therapeutics' return on equity of -0.14% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Esperion Therapeutics currently has a consensus price target of $5.54, suggesting a potential upside of 75.32%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 23.81%. Given Esperion Therapeutics' higher probable upside, research analysts plainly believe Esperion Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Esperion Therapeutics has higher revenue and earnings than Lifecore Biomedical. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A

In the previous week, Esperion Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Esperion Therapeutics' score of 1.42 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Esperion Therapeutics beats Lifecore Biomedical on 10 of the 14 factors compared between the two stocks.

How does Lifecore Biomedical compare to Evommune?

Lifecore Biomedical (NASDAQ:LFCR) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Evommune has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Evommune's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Evommune	N/A	N/A	N/A

Lifecore Biomedical has higher revenue and earnings than Evommune. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Evommune	$13M	36.79	-$68.87M	-$9.50	N/A

Lifecore Biomedical presently has a consensus price target of $6.50, suggesting a potential upside of 23.81%. Evommune has a consensus price target of $45.63, suggesting a potential upside of 243.59%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Evommune had 11 more articles in the media than Lifecore Biomedical. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Evommune's score of -0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evommune	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Evommune beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Vor Biopharma?

Lifecore Biomedical (NASDAQ:LFCR) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential upside of 23.81%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 129.49%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Vor Biopharma has lower revenue, but higher earnings than Lifecore Biomedical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Vor Biopharma's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Vor Biopharma	N/A	N/A	N/A

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Vor Biopharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Summary

Vor Biopharma beats Lifecore Biomedical on 10 of the 13 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$186.05M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-5.59	20.90	27.51	24.87
Price / Sales	1.53	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	12.50	8.75	11.01	6.54
Net Income	-$35.26M	$23.81M	$3.57B	$336.70M
7 Day Performance	-9.48%	3.60%	2.31%	2.88%
1 Month Performance	8.25%	3.72%	1.38%	0.64%
1 Year Performance	-34.05%	68.80%	36.70%	31.34%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.6951 of 5 stars	$5.25 +5.8%	$6.50 +23.8%	-35.3%	$186.05M	$128.87M	N/A	690	News Coverage Positive News
ANNX Annexon	3.3943 of 5 stars	$5.28 +4.8%	$16.00 +203.0%	+137.9%	$825.77M	N/A	N/A	60	Positive News High Trading Volume
SLDB Solid Biosciences	2.5604 of 5 stars	$8.79 +5.9%	$17.00 +93.4%	+105.1%	$817.13M	N/A	N/A	100
ESPR Esperion Therapeutics	2.7145 of 5 stars	$3.16 flat	$5.54 +75.3%	+221.0%	$814.31M	$403.14M	N/A	200
EVMN Evommune	2.23 of 5 stars	$24.28 +7.7%	$49.25 +102.8%	N/A	$812.21M	$13M	N/A	45	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ANNX, SLDB, ESPR, EVMN, and VOR

How does Lifecore Biomedical compare to Annexon?

Summary

How does Lifecore Biomedical compare to Solid Biosciences?

Summary

How does Lifecore Biomedical compare to Esperion Therapeutics?

Summary

How does Lifecore Biomedical compare to Evommune?

Summary

How does Lifecore Biomedical compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ANNX, SLDB, ESPR, EVMN, and VOR

How does Lifecore Biomedical compare to Annexon?

Which has more risk & volatility, ANNX or LFCR?

Does the media refer more to ANNX or LFCR?

Do insiders and institutionals have more ownership in ANNX or LFCR?

Is ANNX or LFCR more profitable?

Which has higher earnings & valuation, ANNX or LFCR?

Do analysts rate ANNX or LFCR?

Summary

How does Lifecore Biomedical compare to Solid Biosciences?

Is SLDB or LFCR more profitable?

Which has more volatility and risk, SLDB or LFCR?

Do institutionals & insiders believe in SLDB or LFCR?

Does the media refer more to SLDB or LFCR?

Which has preferable earnings & valuation, SLDB or LFCR?

Do analysts prefer SLDB or LFCR?

Summary

How does Lifecore Biomedical compare to Esperion Therapeutics?

Do insiders and institutionals believe in ESPR or LFCR?

Is ESPR or LFCR more profitable?

Which has more risk & volatility, ESPR or LFCR?

Do analysts recommend ESPR or LFCR?

Which has stronger earnings & valuation, ESPR or LFCR?

Does the media refer more to ESPR or LFCR?

Summary

How does Lifecore Biomedical compare to Evommune?

Is LFCR or EVMN more profitable?

Which has better valuation & earnings, LFCR or EVMN?

Do analysts recommend LFCR or EVMN?

Do insiders and institutionals hold more shares of LFCR or EVMN?

Does the media prefer LFCR or EVMN?

Summary

How does Lifecore Biomedical compare to Vor Biopharma?

Do analysts rate LFCR or VOR?

Which has preferable earnings & valuation, LFCR or VOR?

Is LFCR or VOR more profitable?

Do insiders and institutionals believe in LFCR or VOR?

Does the media prefer LFCR or VOR?

Which has more risk & volatility, LFCR or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools